CSU Pipeline Update: Barzolvolimab Shows Efficacy and Safety at 1 Year
Celldex Therapeutics, Inc.’s barzolvolimab showed sustained and deepening efficacy plus well-tolerated safety in chronic spontaneous urticaria (CSU) across a 52-week study, according to data presented at the European Academy of Dermatology and Venereology (EADV) Congress in Amsterdam. Barzolvolimab specifically targets mast cells by binding the receptor tyrosine kinase KIT with high specificity and potently inhibiting […]